NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 5.16 against a street estimate of 4.00 — a beat of 29.0%.
with an average price target of ₹881.25.
| Document | Date |
|---|---|
| Annual report FY2026 SHILPA MEDICARE LIMITED – ANNUAL REPORT FY26 SUMMARY HEADLINE NUMBERS • Total Income: ₹1,549 Crores (+18% YoY) • EBITDA: ₹445 Crores (+30% YoY) • Co | 2026-08-13 |
| Q1 FY27 earnings call SHILPA MEDICARE LIMITED – Q1 FY27 RESULTS SUMMARY HEADLINE NUMBERS • Quarterly Revenue: INR 469 crores, up 43% year-on-year – highest ever quarterly | 2026-08-10 |
| Investor presentation · Q1 FY27 SHILPA MEDICARE LIMITED – 1QFY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Total Revenue: INR 469 crores (+43% YoY; +7% QoQ) – highest quarterly reve | 2026-08-05 |
| Quarterly results · Q1 FY27 SHILPA MEDICARE LIMITED – Q1 FY2026-27 SUMMARY HEADLINE NUMBERS • Standalone Q1 FY2026-27 (Quarter ended June 30, 2026): - Total Income: Rs 19,860 | 2026-08-05 |
| Q4 FY26 earnings call SHILPA MEDICARE LIMITED – Q4 FY26 RESULTS SUMMARY HEADLINE NUMBERS • Q4 FY26 revenue: INR 439 crores, up 30% YoY • Full year FY26 revenue: INR 1,549 | 2026-05-26 |
| Investor presentation · Q4 FY26 SHILPA MEDICARE LIMITED – FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: INR 1,549 crores (+18% YoY); Q4FY26 Revenue: INR 439 crores ( | 2026-05-22 |
| Q3 FY26 earnings call SHILPA MEDICARE LIMITED – Q3 FY26 RESULTS SUMMARY HEADLINE NUMBERS • Q3 FY26 revenue: INR 411 crores (highest ever quarterly), +28% YoY • 9-month FY | 2026-02-10 |
| Quarterly results · Q3 FY26 SHILPA MEDICARE LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS STANDALONE – QUARTER ENDED 31 DECEMBER 2025 (UNAUDITED) • Total Income: Rs 17,699.27 la | 2026-02-06 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.60 / share ex-date Sep 4, 2026 | 2026-09-04 |
| Bonus issue | 1 : 1 ex-date Oct 3, 2025 | 2025-10-03 |
| Dividend | ₹1 / share ex-date Sep 17, 2025 | 2025-09-17 |
| Announcement | Date |
|---|---|
| Commissioning of state-of-art Antibody Drug Conjugate GMP manufacturing facility Shilpa Medicare Limited announced that its subsidiary, Shilpa Biologicals Private Ltd, has commissioned a new state-of-the-art manufacturing facility for Antibody Drug Conjugate (ADC) produc | 2026-06-24 |
| NCLT order certified for amalgamation/merger Shilpa Medicare Limited has informed the Exchange about certified true copy of NCLT order | 2026-03-17 |
| Signed definitive agreement to sell 31% stake in subsidiary Shilpa Medicare Limited has signed a definitive agreement to sell a 31% stake in its subsidiary, Sravathi Advance Process Technologies Pvt Ltd. This is a partial divestment of the company's | 2025-10-27 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Shilpa Medicare Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.